Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty for Hip Fracture
Sponsor: Pluristem Ltd.
Listed as NCT03451916, this PHASE3 trial focuses on Hip Fracture and remains completed. Sponsored by Pluristem Ltd., it has been updated 14 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 9 earlier versions
-
Jan 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
May 2019 — Aug 2020 [monthly]
Recruiting PHASE3
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pluristem Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berlin, Germany , Denver, United States , Dresden, Germany , Haifa, Israel , Indiana, United States , Jerusalem, Israel , Kfar Saba, Israel , Münster, Germany , Oxford, United Kingdom , Ramat Gan, Israel and 4 more locations